help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on July 18, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-0676
A more recent version of this article appeared on October 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
91/10/3891    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kauppinen-Mäkelin, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kauppinen-Mäkelin, R.

Submitted on March 28, 2006
Accepted on July 10, 2006

Quality of life in treated patients with acromegaly

Ritva Kauppinen-Mäkelin*, Timo Sane, Harri Sintonen, Helene Markkanen, Matti J. Välimäki, Eliisa Löyttyniemi, Leo Niskanen, Antti Reunanen, Ulf-Håkan Stenman, and the Finnish Acromegaly Study Group

Department of Internal Medicine (R.K.-M.), Jorvi Hospita1, FIN-02740 Espoo, Finland; Division of Endocrinology (T.S., M.J.V.), Department of Medicine, and Department of Clinical Chemistry (H.M., U.-H.S.), Helsinki University Central Hospital, FIN-00029 Helsinki, Finland; Department of Public Health (H.S.), University of Helsinki, FIN-00014 Helsinki, Finland; Department of Statistics (E.L.), University of Turku, FIN-20014 Turku, Finland; Department of Medicine (L.N.), Kuopio University Hospital, FIN-70211 Kuopio, Finland; National Public Health Institute (A.R.), FIN-00300 Helsinki, Finland

* To whom correspondence should be addressed. E-mail: ritva.kauppinen-makelin{at}hus.fi.

Context: It is not known, to what extent quality of life (QoL) of patients treated for acromegaly is dependent on levels of GH and IGF-1 attained.

Objective: To examine the health-related quality of life (HRQoL) and its dependence on treatment outcome and modality in a nationwide survey of acromegalic patients.

Design, setting and patients: All eligible patients with acromegaly, diagnosed during January 1980 and December 1999 in Finland, were invited to a follow-up study, carried out 11.4 ± 5.7 (mean±SD) years after initial treatment. HRQoL of the patients, measured by the generic 15D instrument, was compared with that of the general population. Factors related to HRQoL were analyzed by logistic regression.

Main outcome measure: HRQoL.

Results: Of 277 eligible patients, 231 (83.4%) participated in the follow-up study. Of them, 51.1% were in remission according to consensus criteria.

The patients reported reduced HRQoL in comparison to the age- and gender-standardized general population (P < 0.001). HRQoL was related to nadir GH in oral glucose tolerance test (GHOGTT) in an inverted U-shaped fashion (overall P = 0.021). Patients with GHOGTT nadir values between 0.3 and 1.0 µg/l had a better HRQoL than those with lower or higher values. A normal IGF-1 (P = 0.038) and not having had radiotherapy (P = 0.004) were also associated with a better HRQoL.

Conclusions: HRQoL is reduced in treated patients with acromegaly. The best HRQoL may be achieved by normalization of IGF-1 and by targeting the GHOGTT nadir to levels between 0.3 µg/l and 1.0 µg/l. Radiotherapy is associated with adverse HRQoL.
Key words: acromegaly • growth hormone • IGF-1 • quality of life




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
L.-L. Norrman, G. Johannsson, K. S. Sunnerhagen, and J. Svensson
Baseline Characteristics and the Effects of Two Years of Growth Hormone (GH) Replacement Therapy in Adults with GH Deficiency Previously Treated for Acromegaly
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2531 - 2538.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. P Matta, E. Couture, L. Cazals, D. Vezzosi, A. Bennet, and P. Caron
Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance
Eur. J. Endocrinol., March 1, 2008; 158(3): 305 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. T'Sjoen, M. Bex, D. Maiter, B. Velkeniers, and R. Abs
Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly
Eur. J. Endocrinol., October 1, 2007; 157(4): 411 - 417.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Hahner, M. Loeffler, M. Fassnacht, D. Weismann, A.-C. Koschker, M. Quinkler, O. Decker, W. Arlt, and B. Allolio
Impaired Subjective Health Status in 256 Patients with Adrenal Insufficiency on Standard Therapy Based on Cross-Sectional Analysis
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3912 - 3922.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M Kars, A A van der Klaauw, C S Onstein, A M Pereira, and J A Romijn
Quality of life is decreased in female patients treated for microprolactinoma
Eur. J. Endocrinol., August 1, 2007; 157(2): 133 - 139.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society